

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/028507 A1

- (51) International Patent Classification⁷: **A61K 9/20**, 31/506
- (21) International Application Number: PCT/EP2003/050627
- (22) International Filing Date:
17 September 2003 (17.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
02078968.1 24 September 2002 (24.09.2002) EP
- (71) Applicant (for all designated States except US): **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DE HAAN, Pieter** [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss (NL). **VAN LARE, Coert, Elisabeth, Johannes** [NL/NL]; N.V. Organon, P.O.Box 20, NL-5340 BH Oss (NL).
- (74) Agent: **KRAAK, H.**; P.O. Box 20, NL-5340 BH Oss (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD TO IMPROVE PHARMACEUTICAL TABLETS HAVING A MATRIX OF CELLULOSE ETHER

(57) Abstract: This invention provides for a packaged tablet, which tablet has a matrix consisting of at least 55% of a cellulose ether, whereby the tablet has a water activity of at most 0.6 and is packaged such as to delay moisture uptake by the tablet in order to decrease the vulnerability of the tablet to abrasion and attrition.

WO 2004/028507 A1

METHOD TO IMPROVE PHARMACEUTICAL TABLETS HAVING A MATRIX OF CELLULOSE ETHER

The invention relates to a packaged tablet, which tablet has a matrix
5 consisting of at least 55% of a cellulose ether.

Such packaged tablets are generally known and usually the package is intended to protect the tablets from being polluted. Other characteristics of packaging can be intended to conveniently remove individual tablets
10 from the package by the end users of the tablets.

Tablets having a matrix consisting of at least 55% of a cellulose ether turn out to be vulnerable to damage of the surface due to mechanical wear and tear. The problem is present from the moment in the production process that the tablets are leaving the tablet compression machine up to the
15 moment at which such tablets are removed from the package and handheld by the person in need of using the medicine in the tablet. The problem is visible on conventionally packed tablets from powder in the bulk package of tablets, powder in bottles of tablets and powder in the single tablet pockets of a patient pack. The powder consists of loosened
20 tablet material due to abrasion, which is wear of the tablets due to contact among the tablets or due to attrition, which is wear of the tablets due to contact against other material. Also, an unacceptable amount of dust forms during processing the tablets, for example, during manual or automatic blistering.

25 Tablets of the defined characteristics can be prepared by dry-mixing processes whereby the tablets are manufactured by direct compression of a powder mixture or by compressing a preformed granulate into a tablet without the use of granulation liquids.

A known method to solve a problem of dust formation is treating the tablet
30 surface with coating materials and thereby adding a layer of another composition to the tablets. The purpose of this invention is to reduce the dust formation during handling the tablets without using any additional coating materials.

Testing of tablets conditioned to different humidity conditions showed a reduction in dust formation with decreasing relative humidity storage condition (thus decreasing moisture content).

- 5 It has now been found that there is reduced dust formation with packaged tablets which have a water activity of at most 0.6 and the tablets are packaged such as to delay moisture uptake by the tablets. Preferred are packaged tablets which have a water activity of at most 0.55, but lower water activity, such as 0.50 or even less than 0.45, is preferred.
- 10 Such packaged tablets have decreased vulnerability to abrasion and attrition.

The term water activity is used as is known from the thermodynamic concept of activity of chemical compounds. The activity is defined here to
15 be measured at 25 °C and 1 Atmosphere. The term is a quantitative term describing the availability of water for any chemical interaction. In pharmaceutics it is commonly used in sorption isotherms which describe the relation between water content of a product and the corresponding relative humidity (RH) of the air in equilibrium with the product at that
20 water content. The equilibrium RH is directly correlated to the water activity, that is: $\text{Water Activity} = \text{RH}/100$. In tablets having about 80% hydroxypropylmethylcellulose as matrix substance, a water activity of 0.6 in the tablets corresponds approximately to 9.0 % w/w water content. The latter water content is defined as the content of water determined by the
25 Karl-Fischer method, implying that this water content includes, for example, the amount of crystal water of the ingredients of the tablet. Thus the invention provides for packaged tablets having less than 9 w/w % water content having reduced dust formation.

Tablets having a matrix consisting of at least 55% of a cellulose ether are
30 the kind of tablets with the cumbersome dust forming surface if not treated with the method according to the invention. It is the high content of the cellulose ether and the properties of the matrix which cause the tablets having such a vulnerable surface. Since the problem of dust formation with tablets having a matrix consisting of a cellulose ether can
35 also be influenced by the nature and amounts of other constituents, such as the filler or binder and active ingredient, the method according to the

present invention is preferably to be applied to tablets having a matrix which consists of at least 65% of the cellulose ether and more preferably of from 70 to 85 wt % of the cellulose ether. Also, a reduced amount of carbohydrate binder, such as Avicel, which is microcrystalline cellulose, can be problematic for untreated tablets. More specifically, for example less than 15% and in particular less than 10 wt % is problematic for untreated tablets. Tablets with carbohydrate binders are for example cellulose (7 to 10 wt% microcrystalline cellulose, such as Avicel pH 101), sugars, starches, amylopectin, dextrin, maltodextrin, gums and alginates.

10

After preparing the tablets under the suitable low water activity condition the water content should be maintained at reduced level by protecting the tablets from environmental moisture, hence the recommended packaging having the property to delay moisture uptake by the tablets. Such

15 packaging is well known in the art of pharmaceutical packaging. The

Remington; The Science and Practice of Pharmacy; 20th ed., Publisher: Lippincott Williams & Wilkins; Baltimore; USA in Chapter 54: Plastic packaging materials, under the heading of mass transfer on page 1006.

20 Packaging materials are available which protect tablets adequately from water vapor, providing a barrier to moisture, thereby hampering transfer of water towards the tablets in the package. Examples of packages having the property to delay moisture uptake by the tablets are containers that are closed by sealing, or blistered tablets in an aluminium sachet. It is
25 therefore another aspect of this invention to provide a patient pack comprising one or more tablets having a matrix consisting of at least 55% of a cellulose ether whereby the tablet has a water activity of at most 0.6 and the package is such as to delay moisture uptake by the tablets. Other specific examples of packaged tablets according to the invention are
30 bottles of 75 cc made of amber glass with 38 mm closure and comprising a canister or sachet with a desiccant and containing 30-50 tablets per bottle. Another embodiment is a capped and sealed high density polyethylene (HDPE) bottle with desiccant canister. The closures can be lined with an inner seal consisting of pulpboard/wax/foil laminate which
35 is affixed to the inner cap. Packaged tablets according to the invention can also be in a can or in aluminium-aluminium blister package or in a

normal blister package which is further provided with an Aclar® film. Aclar is a flexible material made from fluorinated chlorinated resins, such as, e.g., Aclar22®, which is a polymer from chlorotrifluoroethene and 1,1-difluoroethene monomers. The use of polyvinylidichloride (PVDC) or poly-
5 ethyleneterephthalate (PET) are useful packaging materials to delay moisture uptake by the tablets.

- Cellulose ethers are used as carrier in dry-mix tablets, as binder in wet-granulation and can be used in coating techniques as film-forming polymers. Such carriers tend to retain in aqueous environment other
10 ingredients for a longer time upon absorption of water in the outer layer and consequently are suitable for extended release formulation. Examples of such carriers can be found in the group of hydroxy-(1C-3C)alkyl(1C-3C)alkylcelluloses, such as hydroxymethylcellulose, hydroxyethylcellulose and the preferred hydroxypropylmethylcellulose (HPMC). Other gel-
15 forming carriers can be found in the standard compilation of pharmaceutically acceptable carriers and excipients, the Handbook of Pharmaceutical Excipients (3rd edition edited by Arthur H. Kibbe; Published by the American Pharmaceutical Association, Washington D.C. and The Pharmaceutical Press, London in 2000).
- 20 The cellulose ethers and the relevant theoretical views on their properties are discussed in Alderman, A., A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms, Int. J. Pharm. Tech. & Prod. Mfr., Vol 5, pages 1-9, 1984.
- 25 The tablets for which the present invention can be used can have a total weight of at most 450 mg and may have a high relative amount of the active ingredient gepirone HCl, e.g. 60, 80, or up to 85 mg gepirone HCl, over the cellulosic polymer matrix material and also over the carbohydrate binder. With the present invention such tablets could still be used without
30 unacceptable dust formation during handling.

Tablets having the composition as shown in Table 1 were prepared.

Table 1: Composition of example tablets; quantities are in mg

Ingredients	20 mg	40 mg	60 mg	80 mg	Function
Gepirone HCl	20.0	40.0	60.0	80.0	Active principle
Hydroxypropyl Methylcellulose (Methocel K100M, Premium)	290.0	290.0	290.0	290.0	Drug release controlling polymer
Microcrystalline Cellulose (Avicel pH 101)	61.8	52.12	31.0	33.7	Diluent
Euroxide, yellow ferric oxide and/or red ferric oxide (E7055, E7056 or E7016)	0.40	0.08	1.2	3.5	Colorant
Colloidal anhydrous silicon dioxide (cab-o- sil M5)	1.60	1.60	1.60	1.60	Glidant
Magnesium stearate NF	1.20	1.20	1.20	1.20	Lubricant

5 Active pre-mixture:

Transfer the colloidal silicon dioxide, NF, colorant (40 mg: Euroxide Yellow E 7056; 60 mg: Euroxide Yellow E 7055; 80 mg: Euroxide yellow E 7055 and Euroxide Red E 7016), gepirone HCl powder and 20% of hydroxypropyl methylcellulose USP in 2 cu. Ft. planetary mixer (Hobart mixer). Mix ingredients for 15 minutes in a planetary mixer (Hobart Mixer). Label as 'Active Pre-Mix'.

Blend for slugging

Mill the Active Pre-Mix in a Fitzmill using a perforated plate No. 0020 at high speed, impact forward to deagglomerate lumps, if any.

Transfer the Active Pre-Mix in a 10 cu. Ft. "V"-blender without an I-bar, while passing through #12 mesh screen and transfer the balance of 80% HPMC, microcrystalline cellulose, NF and 50% of magnesium stearate, NF in the V-blender without an I-bar. Blend ingredients in the V-blender
5 without an I bar for 24 minutes and label as "Blend for Slugging".

Slugging

Compress the blend into slugs using 7/8" round flat face tooling using a rotary Kikusui-Hercules compression machine.

10 In process controls:

Weight:	2250 mg
Hardness:	7 kp
Targeted thickness:	0.255"

Final Blend

Mill the slugs in an S.S. Fitzmill with screw feeder using a perforated plate No. 0093 at medium speed, knives forward and screw feeder setting of 3.5
15 ± 0.5 . Transfer the milled mass into a 10 cu. Ft. S.S. V-blender without I-bar. Screen the balance of 50% magnesium stearate, NF through # 18 mesh and transfer also into the V-blender. Blend for 6 minutes.

Compress tablets with a rotary Kikusui-Libra compression machine using
20 0.338" X 0.405" Ovoid rectangular dies.

In process controls:

Strength, mg	40 & 60	80
Run Weight, mg	385 \pm 27	410 \pm 29
Hardness, kp	18 \pm 4	20 \pm 8
Thickness, inches	0.230 to 0.260	0.235 to 0.265

Testing for vulnerability of the tablets to abrasion and attrition.

25

Tablets of two different strengths of gepirone HCL with compositions according to Table 1 were conditioned for 1 week to defined relative humidities in order to equilibrate the tablet to acquire different water activities. After this the tablets were tested for dust determination with the

following method: 10 tablets are placed for 45 minutes in a Securitainer of Ø 49 x h 58 mm and shaken using a vibrating table at 200 rpm with a horizontal amplitude of 45 mm. The mass loss of the tablets is determined by weighing. Before weighing the tablets are cleaned by vacuum air. The

5 water content of tablets conditioned to the various water activities was determined by adding the water content before conditioning, as determined by the method according to Karl-Fischer, to the weight increase due to water uptake after conditioning of the tablets in the various relative humidities at temperature of 25 °C and 1 atmosphere

10 pressure.

Table 2: Average percentages dust formed using shaking table method.

Gepirone content of tablet	Water activity	Dust formed in % w/w of tablet weight	Water content in % w/w of tablet weight
20 mg	0.43	1.65	6.4
20 mg	0.60	2.01	9.0
20 mg	0.75	3.42	11.7
80 mg	0.43	2.11	4.7
80 mg	0.60	2.93	7.2
80 mg	0.75	4.33	9.7

The results demonstrate that the vulnerability for dust formation

15 increases with increasing water activity in the tablets. A significant increase in dust formation occurs at water activities higher than 0.6.

Claims

1. A packaged tablet, which tablet has a matrix consisting of at least 55%
of a cellulose ether, characterised in that the tablet has a water activity
5 of at most 0.6 and is packaged such as to delay moisture uptake by the
tablet.
2. The packaged tablet according to claim 1, characterised in that the
tablet has a water activity of less than 0.55.
- 10 3. A packaged tablet, which tablet has a matrix consisting of at least 55%
of a cellulose ether, characterised in that the tablet has a water content
of less than 9 % w/w and is packaged such as to delay moisture uptake
by the tablet.
- 15 4. The packaged tablet according to any one of claim 1-3, characterised in
that the matrix consists of more than 65% of a cellulose ether.
5. The packaged tablet according to claim 4. characterised in that the
20 cellulose ether is hydroxypropyl methylcellulose.
6. The packaged tablet according to any one of claims 1-5, characterised
in that the tablet comprises gepirone HCl in an amount in the range of
from 20 – 85 mg.

INTERNATIONAL SEARCH REPORT

International Classification No

PCT/EPC/50627

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K9/20 A61K31/506

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 369 172 A (SCHOR JOSEPH M ET AL) 18 January 1983 (1983-01-18) column 4, line 20-65; examples 1-4 claims 1,2	1-5
X	WO 02 45753 A (AKZO NOBEL NV) 13 June 2002 (2002-06-13) page 4, line 15 -page 5, line 29; example 1 claims 1,2	1-6
X	EP 0 700 680 A (SQUIBB BRISTOL MYERS CO) 13 March 1996 (1996-03-13) claims 1,3,14	1-6
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

23 January 2004

Date of mailing of the international search report

05/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hedegaard, A

INTERNATIONAL SEARCH REPORT

International Publication No

PCT/EP/50627

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 430 684 A (LOWEY H) 31 March 1976 (1976-03-31) examples III-VI column 5, line 19-26 claims 1,2,5 -----	1-5
X	US 4 259 314 A (LOWEY HANS) 31 March 1981 (1981-03-31) column 4, line 39 -column 5, line 9 claims 1,5,7 -----	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/50627

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4369172	A	18-01-1983	AR 228699 A1	30-03-1983
			BE 895391 A1	15-04-1983
			CA 1195929 A1	29-10-1985
			CH 641670 A5	15-03-1984
			DE 3246492 A1	30-06-1983
			DK 560782 A ,B,	19-06-1983
			ES 8402155 A1	16-04-1984
			FR 2518409 A1	24-06-1983
			GB 2111386 A ,B	06-07-1983
			IL 67497 A	28-02-1986
			IT 1164472 B	08-04-1987
			JP 1812257 C	27-12-1993
			JP 5009413 B	04-02-1993
			JP 58110513 A	01-07-1983
			MX 160316 A	01-02-1990
			NL 8204893 A ,B,	18-07-1983
			SE 453796 B	07-03-1988
			SE 8207167 A	19-06-1983
			ZA 8209267 A	31-08-1983
WO 0245753	A	13-06-2002	AU 2637102 A	18-06-2002
			CA 2436692 A1	13-06-2002
			CZ 20031589 A3	12-11-2003
			WO 0245753 A2	13-06-2002
			EP 1343504 A2	17-09-2003
			NO 20032581 A	06-06-2003
			SK 6942003 A3	07-10-2003
EP 0700680	A	13-03-1996	US 5478572 A	26-12-1995
			AT 186462 T	15-11-1999
			AU 702282 B2	18-02-1999
			AU 3043895 A	21-03-1996
			CA 2157323 A1	07-03-1996
			CN 1128142 A ,B	07-08-1996
			CY 2222 A	18-04-2003
			CZ 9502275 A3	13-03-1996
			DE 69513254 D1	16-12-1999
			DE 69513254 T2	15-06-2000
			DK 700680 T3	01-05-2000
			EP 0700680 A1	13-03-1996
			ES 2142432 T3	16-04-2000
			FI 954154 A	07-03-1996
			GR 3032598 T3	31-05-2000
			HK 1014666 A1	21-07-2000
			HU 73182 A2	28-06-1996
			IL 114984 A	28-10-1999
			JP 8183736 A	16-07-1996
			NO 953212 A	07-03-1996
			NZ 272855 A	26-05-1997
			PL 310298 A1	18-03-1996
			RU 2155044 C2	27-08-2000
			SG 30436 A1	01-06-1996
			TW 445152 B	11-07-2001
			ZA 9507144 A	26-03-1996
GB 1430684	A	31-03-1976	CA 1018456 A1	04-10-1977
			DE 2332484 A1	10-01-1974
			DK 146434 B	10-10-1983

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Publication No

PCT/EP/50627

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1430684	A	FR 2190409 A1	01-02-1974
		JP 49054519 A	27-05-1974
		NL 7308859 A , B,	28-12-1973
US 4259314	A 31-03-1981	AR 225478 A1	31-03-1982
		CH 644759 A5	31-08-1984
		DE 3045634 A1	11-06-1981
		FR 2471786 A1	26-06-1981
		GB 2065145 A , B	24-06-1981
		IT 1134636 B	13-08-1986
		JP 1858446 C	27-07-1994
		JP 5067612 B	27-09-1993
		JP 62123133 A	04-06-1987
		JP 1722018 C	24-12-1992
		JP 4004301 B	27-01-1992
		JP 56092816 A	27-07-1981
		SE 446060 B	11-08-1986
		SE 8008646 A	11-06-1981